The Daily Brief

October 25, 2026

A cascade of legal challenges is upending Texas's patchwork cannabis regulations, as hemp companies, smokable THC retailers, and cannabis industry players mount coordinated lawsuits against the state's increasingly restrictive rules. Another lawsuit was filed this week seeking to overturn Texas's ban on smokable THC and its sharp increase in licensing fees for manufacturers and retailers—joining existing legal challenges from hemp shops already contested against the state over new THC regulations. The legal strategy reflects growing frustration in Texas's cannabis market, where companies face a tightening regulatory environment even as momentum shifts nationally toward normalization. What's unfolding in Texas isn't a unified industry opposing government overreach—it's a fragmented market in open conflict, with different cannabis players fighting over who gets to operate, what products remain legal, and whether the state's restrictions will survive judicial review.

The political landscape is shifting faster than the courtrooms can move. Colin Talarico, a candidate for Texas Senate, has signaled he'll partner with the incoming Trump administration to push federal marijuana legalization if elected, while also committing to work toward federal legalization through Congress if he wins. This represents a notable break from Texas's traditional opposition to cannabis reform—and a calculation that legalization is now a winning political position rather than a liability. The broader national ballot this cycle includes marijuana measures in multiple states, signaling that the debate around cannabis has fundamentally changed from whether to legalize to *how* to regulate it properly.

Houston voters are directly confronting this shift this fall, with ballot measures that would effectively deprioritize cannabis law enforcement and establish misdemeanor marijuana possession as Houston Police Department's lowest priority for enforcement. The same ballot includes a proposal to ban no-knock warrants, a tactic historically used in drug enforcement that has resulted in mistaken raids and loss of life. These measures suggest that even at the local level, Texas communities are moving faster than state lawmakers—pushing enforcement priorities toward harm reduction while the state-level legal system remains gridlocked.

Money The financial stakes are real and growing. Texas's hemp and cannabis sector has scaled beyond underground operation into legitimate retail infrastructure, with licensed shops and manufacturers now facing regulatory rules that some describe as prohibitively expensive. The state's higher licensing fees, combined with restrictions on smokable THC products, are reshaping the market's economics—and generating the legal firepower for the current lawsuit wave. Meanwhile, the fragmentation of Texas's cannabis market means multiple economic winners and losers depending on which regulations survive judicial challenge.

The regulatory chaos reveals a deeper problem: Texas has banned several THC products while simultaneously allowing others, creating a legal framework so unclear that even industry participants struggle to understand what's permitted. This uncertainty accelerates the litigation cycle—companies can't plan long-term investments when the legal landscape shifts monthly, and neither state nor business has clarity on the rules that will actually stand. Context Texas is spending resources banning a product that zero Americans have ever fatally overdosed on, while alcohol remains completely legal despite killing roughly 95,000 Americans annually. The disconnect between regulatory energy and public health outcomes suggests the state's cannabis policy is driven by inertia rather than evidence.

October 25, 2026

The global cannabis market is on track to nearly double in size over the next five years, with research firm ResearchAndMarkets projecting growth from $45.6 billion in 2025 to $79.3 billion by 2030—an 11.7% compound annual growth rate. That expansion is being driven by three converging forces: the rise of cannabis-derived pharmaceuticals, expansion of legal retail operations, and booming demand for extraction and testing services. Major multi-state operators like Curaleaf, Trulieve, Green Thumb Industries, Verano, and Cresco Labs are positioned as consolidators in an intentionally fragmented market, where regional licensing requirements prevent any single player from achieving national dominance.

Money The earnings picture from the industry's largest retailers reveals a sector maturing toward profitability. Trulieve posted $298 million in Q1 revenue with adjusted EBITDA of $106 million, while Green Thumb Industries—the only major retailer to report a profit last quarter—hit $275.8 million in revenue with $90.5 million in adjusted EBITDA. Curaleaf, the sector's largest by revenue, reported $338.9 million in Q1 sales with $76.7 million in adjusted EBITDA. Across the board, net losses are shrinking dramatically; Trulieve's net loss fell 32% quarter-over-quarter to $23 million. Trulieve's recent listing on the New York Stock Exchange—a historic first for a U.S. cannabis operator—has unlocked institutional access and boosted its stock 28% year-to-date, signaling investor confidence in a maturing business model.

Virginia's legislature just passed bills to legalize adult-use cannabis sales, ending a five-year gap since the state legalized home cultivation. The state's five existing medical licensees can transition to adult-use operations by November 2026 under the House version, or January 2027 under the Senate version, with one-time transition fees between $5 million and $15 million. Meanwhile, New York is exploring an unusual retail strategy: allowing liquor stores to sell low-THC cannabis beverages through a structured permit system, a move designed to expand legal access while undercutting the illicit market. These regulatory expansions are unlocking capital for operators and ancillary businesses like AFC Gamma, a commercial mortgage REIT now deploying $10 million to $100 million loans across cannabis operators in 15 states.

The cannabis sector faces structural headwinds that investors are watching closely. Section 280E, a 1982 tax rule that prohibits cannabis companies from deducting ordinary business expenses, artificially inflates effective tax rates and drains cash flow—though federal rescheduling could change this. Wholesale price compression in states with mature markets like California and Colorado is eroding retail and wholesale margins across the industry, forcing operators to defend profitability through scale and efficiency. Yet the regulated market alone is expected to reach $43 billion by 2030, more than double today's $29.1 billion, creating a clear mathematical advantage for companies operating legally over the unregulated illicit market that generates no tax revenue and offers no consumer protections.

Context Cannabis operators are now filing quarterly earnings with the SEC and trading on major exchanges, subject to the same corporate governance and financial disclosure rules as alcohol producers, pharmaceutical companies, and every other legal industry. Yet cannabis companies pay federal income taxes on gross revenue—not net profit—while being forbidden from deducting basic business expenses, a tax structure applied to almost no other legal sector. What happens when that contradiction finally resolves?

October 25, 2026

Texas hemp industry wins a reprieve—but faces a narrowing legal path as courts and Congress wrestle with the future of THC products.

On May 1, 2026, Travis County District Court Judge Daniella DeSeta Lyttle issued a temporary injunction blocking Texas Department of State Health Services rules that would have banned smokable hemp across the state. The ruling extends through trial on July 27, keeping THCA flower, pre-rolls, and related products on shelves at retailers like Austin Cannabis Co. and the Austin-based D8 Austin dispensary. But the same morning, the Texas Supreme Court ruled in Sky Marketing Corp. v. DSHS that the health department does have authority to schedule synthetic cannabinoids like delta-8 and HHC—a door that could eventually swing shut on products that aren't naturally occurring in cannabis plants. None of those compounds have been banned yet, but the legal foundation is now in place. Context The distinction matters: naturally occurring trace THC is legal under the 2019 Texas Farm Bill, but the state is carving out a separate pathway to ban manufactured versions of compounds that hemp plants can produce.

The underlying conflict began when Gov. Greg Abbott issued an executive order in fall 2025, after the Texas Legislature spent months deadlocked on whether to regulate hemp products or ban them entirely. Acting on that order, DSHS finalized new rules in March that redefined "total THC" to include THCA—a cannabinoid that converts to delta-9 THC when heated. THCA flower, which accounts for over 70 percent of intoxicating hemp sales at some retailers, would no longer comply with the federal 0.3 percent delta-9 limit. The rules also raised licensing fees sharply: Money retail registration climbed from $150 to $5,000 annually and manufacturer registration from $250 to $10,000 annually—a 33 to 40 percent increase that industry leaders warned would force closures and cut jobs. Todd Harris, co-owner of Happy Cactus, told the court he was planning a third location if the injunction held but might have to shutter his east Austin store if it didn't. Kenneth Burner, who runs Burner's Vape, Smoke and Herb in Galveston County and employs 10 people including veterans and military families, expressed concern that legal consumers would be pushed into unregulated markets.

The federal picture is equally volatile. Most hemp-derived THC products remain protected until December 11, 2026, when a congressional extension expires—and the outcome depends on negotiations that have shifted from simple delay tactics to actual regulatory design. Rep. Beth Van Duyne, a Texas Republican, is pushing the White House to adopt a regulated framework for hemp-derived THC beverages modeled on alcohol rules: age restrictions, taxation, serving limits, marketing controls, and a ban on synthetic cannabinoids. Rep. Morgan Griffith is openly calling for compromise around third-party testing and a broader regulatory structure rather than outright prohibition. But opposition remains organized—Rep. Andy Harris, who helped drive the 2025 federal restrictions, is openly opposing efforts to build a new legal market and is calling for the ban to take effect as scheduled.

The stakes extend beyond boardrooms to veterans and medical users. Many service members rely on legal THC products for PTSD, chronic pain, and anxiety, and state bans force them toward either unlicensed markets or prescription opioids. The interstate shipping question remains legally murky: federal law permits hemp-derived products that meet the 0.3 percent delta-9 standard to cross state lines, but Texas courts have not directly addressed whether consumers can legally receive shipments. A federal judge denied an emergency restraining order on August 10, and a preliminary injunction motion remains pending with no public hearing date scheduled.

Meanwhile, the Texas hemp litigation tracker shows both state and federal cases in motion, each with different timelines and potential outcomes. The July 27 trial date will determine whether the injunction survives, while federal negotiations continue toward December. Money The industry collectively faces a question: stay and fight in court, or start scaling back operations before the deadline. For now, Texas hemp retailers are restocking and selling legally while they can—but operating under the assumption that this window may close.

October 25, 2026

A randomized, double-blind, placebo-controlled clinical trial published this year found that a full-spectrum cannabis formulation with less than 0.3% THC produced statistically significant improvements in autistic children with Level II and Level III autism spectrum disorder. The Harmony study tracked outcomes in overall clinical severity, adaptive functioning, social responsiveness, and affective symptoms after eight weeks—marking a notable shift toward the gold standard of clinical evidence, away from anecdotal parent reports. For years, families and clinicians have struggled with a widening gap between parents' testimonials that cannabis-derived products helped with anxiety, sleep, irritability, and behavior, and a scientific literature too preliminary to establish cannabis as proven treatment. The new trial changes that equation, at least for this specific population and formulation.

A 2025 systematic review found only 11 randomized controlled trials of cannabis-derived treatments for autism met strict inclusion criteria—just four of those produced results in children and adolescents. The certainty of evidence in those studies ranged from very low to low, and researchers concluded that variation among cannabis products and outcome measures made firm conclusions difficult. Notable The Harmony results are significant precisely because they represent rigorous evidence, but they're also preliminary and will require replication before becoming standard clinical practice. Separate 2026 research analyzing the UK Medical Cannabis Registry followed 130 autistic adults receiving cannabis-based medicinal products over as long as 18 months, finding improvements in anxiety, sleep quality, and overall quality of life—but without a control group, researchers could only identify an association, not establish that cannabis itself caused the gains.

Beyond autism, mechanistic research is explaining how cannabinoids actually work on the brain. Northwestern University scientists identified a specific population of somatostatin neurons in the central amygdala—the brain's fear center—that appear to drive cannabis-related anxiety, particularly when stress is already present. In mice given synthetic cannabinoids before exposure to a threatening odor, the drug weakened a natural "brake" on these neurons, making them hyperactive and producing freezing and avoidant behavior. When researchers genetically silenced those same neurons, the anxious response vanished. Notable A good experience can turn bad "pretty quickly if people consume too much cannabis or the situation they are in turns stressful or scary," as the study's senior author, Dr. Sachin Patel of Northwestern's Feinberg School of Medicine, explained—a finding with obvious real-world relevance for anyone considering cannabis use.

The research also reveals how much cannabis chemistry remains unexplored. While THC and CBD dominate public conversation, living cannabis plants primarily produce acidic precursors including THCA, CBDA, and CBGA—molecules that interact with the body differently than their heat-activated, decarboxylated forms. A narrative review in Neuroscience and Biobehavioral Reviews synthesizing research from March 2006 through March 2026 found these acidic cannabinoids influence serotonin signaling, inflammation, calcium regulation, and mitochondrial function in ways distinct from THC and CBD. THCA in particular shows less intoxicating activity than THC, making it potentially useful for therapeutic applications without pronounced intoxication. The authors note that cannabis may contain useful chemistry that remains underexplored—a reminder that a plant with 600 different molecules and roughly 140 cannabinoids still holds surprises.

Preclinical studies continue mapping cannabinoid potential for serious conditions. Researchers at UC Irvine are testing whether THC and CBD act synergistically, antagonistically, or additively in sickle cell disease pain—a condition causing severe persistent pain in roughly 100,000 Americans, mostly of African descent. Current standard-of-care opioids are only partially effective and carry substantial adverse effects. A prior clinical trial testing vaporized cannabis with a 1:1 THC:CBD ratio found significant mood improvement but only a trend toward pain reduction that didn't reach statistical significance; the new study examines whether different THC/CBD ratios and interactions with hydroxyurea (the standard non-opioid medication) matter. If successful, the work could expand treatment options for a population with limited alternatives.

Context What emerges across these studies is a pattern both encouraging and humbling: cannabis research is advancing rapidly, moving from anecdote to controlled trials and mechanistic understanding, yet remains preliminary for most conditions. The science is moving forward, but humanity has not yet reached the finish line. The plant contains underexplored chemistry, context matters enormously—stress turns a positive experience anxious—and rigorous replication is non-negotiable before claiming therapeutic breakthroughs. That's not a reason to dismiss the research. It's a reason to keep funding it seriously.